日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine

接种二价信使RNA严重急性呼吸综合征冠状病毒2疫苗加强免疫后的黏膜和全身抗体反应

Atmar, Robert L; Lyke, Kirsten E; Posavad, Christine M; Deming, Meagan E; Brady, Rebecca C; Dobrzynski, David; Edupuganti, Srilatha; Mulligan, Mark J; Rupp, Richard E; Rostad, Christina A; Jackson, Lisa A; Martin, Judith M; Shriver, Mallory C; Rajakumar, Kumaravel; Coler, Rhea N; El Sahly, Hana M; Kottkamp, Angelica C; Branche, Angela R; Frenck, Robert W; Johnston, Christine; Babu, Tara M; Bäcker, Martín; Archer, Janet I; Crandon, Sonja; Nakamura, Aya; Nayak, Seema U; Szydlo, Daniel; Dominguez Islas, Clara P; Brown, Elizabeth R; O'Connell, Sarah E; Montefiori, David C; Eaton, Amanda; Neuzil, Kathleen M; Stephens, David S; Beigel, John H; Pasetti, Marcela; Roberts, Paul C

Development and Concordance of Binding and Neutralizing Assays to Determine SARS-CoV-2 Antibody Activity in Human Milk.

开发和验证结合和中和试验以确定人乳中 SARS-CoV-2 抗体活性

Shriver Mallory C, Milletich Patricia L, Moreno Alberto, Larsen Sasha E, Posavad Christine M, Berube Bryan J, Wali Bushra, Ellis Madison, Manning Kelly, Moore Kathryn M, Zhu Zhiyi, Grewal Nimrit, Cadena Ines A, Cardemil Cristina V, Munoz Flor M, Neuzil Kathleen M, Coler Rhea N, Suthar Mehul S, Pasetti Marcela F

Safety and Tolerability of ShigActive™, a Shigella spp. Targeting Bacteriophage Preparation, in a Phase 1 Randomized, Double-Blind, Controlled Clinical Trial

ShigActive™(一种靶向志贺氏菌噬菌体的制剂)在 1 期随机、双盲、对照临床试验中的安全性和耐受性

Chen, Wilbur H; Woolston, Joelle; Grant-Beurmann, Silvia; Robinson, Courtney K; Bansal, Garima; Nkeze, Joseph; Permala-Booth, Jasnehta; Fraser, Claire M; Tennant, Sharon M; Shriver, Mallory C; Pasetti, Marcela F; Liang, Yuanyuan; Kotloff, Karen L; Sulakvelidze, Alexander; Schwartz, Jennifer A